Shots:

• The approval is based on the study assessing Ruzurgi vs PBO in 32 adult patients while patients taking Ruzurgi for at least three months prior to entering the study
• The study measured effectiveness of a patient to rise from a chair- walk three meters & return to the chair for three consecutive laps without pause- self-assessment scale for LEMS-related weakness evaluating the feeling of weakening or strengthening which was more in PBO patients and patients experienced less impairment vs PBO
• Ruzurgi tablets is a potassium chain blocker indicated for LEMS and has received FDA’s Priority Review and Fast Track designation as well as Orphan Drug Designations

Click here to read full press release/ article | Ref: Jacobus Pharmaceutical | Image: Signbox